Gene · 483
ATP1B3: ATPase Na+/K+ transporting subunit beta 3
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ATP1B3: ATPase Na+/K+ transporting subunit beta 3. Genes, record 483. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/483
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P54709 | Sodium/potassium-transporting ATPase subunit beta-3 | 279 | 8 | Ensembl, GeneID, HGNC |
Source UniProt
Patents105
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 38340 | P54709 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 3286 | P54709 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 503 | P54709 | Espacenet |
| US 12384828 B2 | 2025-08-12 | 210 | P54709 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 503 | P54709 | Espacenet |
| EP 4572801 A1 | 2025-06-25 | 315 | P54709 | Espacenet |
| EP 4572802 A1 | 2025-06-25 | 315 | P54709 | Espacenet |
| EP 4572803 A1 | 2025-06-25 | 315 | P54709 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 3286 | P54709 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 7557 | P54709 | Espacenet |
1 to 10 of 105
See all 105 patentsDrugs6
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ACETYLDIGITOXIN | CHEMBL3545057 | Sodium/potassium-transporting ATPase inhibitor | INHIBITOR | ChEMBL |
| DESLANOSIDE | CHEMBL1614 | Sodium/potassium-transporting ATPase inhibitor | INHIBITOR | ChEMBL |
| DIGITOXIN | CHEMBL254219 | Sodium/potassium-transporting ATPase inhibitor | INHIBITOR | ChEMBL |
| DIGOXIN | CHEMBL1751 | Sodium/potassium-transporting ATPase inhibitor | INHIBITOR | ChEMBL |
| ISTAROXIME | CHEMBL2093999 | Sodium/potassium-transporting ATPase inhibitor | INHIBITOR | ChEMBL |
| LANATOSIDE C | CHEMBL506569 | Sodium/potassium-transporting ATPase inhibitor | INHIBITOR | ChEMBL |
Trials55
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07272902 | DIGOXIN | ClinicalTrials.gov | ||
| NCT07047209 | DIGOXIN | PHASE2 | ClinicalTrials.gov | |
| NCT07025850 | DIGOXIN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT06701812 | DIGOXIN | PHASE2 | ClinicalTrials.gov | |
| NCT06657404 | DIGOXIN | ClinicalTrials.gov | ||
| NCT06588699 | DIGOXIN | PHASE2 | ClinicalTrials.gov | |
| NCT06322017 | DIGOXIN | ClinicalTrials.gov | ||
| NCT06240403 | DIGOXIN | PHASE2 | ClinicalTrials.gov | |
| NCT06030622 | DIGOXIN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT05975021 | ISTAROXIME | PHASE1/PHASE2 | ClinicalTrials.gov |
1 to 10 of 55
See all 55 trialsNIH grants566
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ATP1B3 papers | Newest fiscal year |
|---|---|---|---|
| P30CA068485 | Cancer Center Support Grant | 7 | 2025 |
| U24CA224309 | Stanford Cancer Immune Monitoring and Analysis Center (CIMAC) | 5 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 4 | 2025 |
| U19AI104209 | Integrated Genomic and Functional Studies of Immunotherapy for Multi-Food Allergy | 4 | 2025 |
| U19AI116484 | Stanford/UNC Biomimetic U19 Research Center | 4 | 2025 |
| P30CA142543 | UT Southwestern Medical Center Simmons Comprehensive Cancer Center | 3 | 2025 |
| T32CA009054 | A Training Program for Interdisciplinary Cancer Research | 3 | 2025 |
| K08CA270417 | Elucidating cancer-intrinsic mechanisms of perineural invasion in pancreatic cancer | 2 | 2025 |
| K08HL159346 | Deep learning to enable the genetic analysis of aorta | 2 | 2025 |
| P01HL136275 | Immune Cell Interactions in Atherosclerosis | 2 | 2025 |
1 to 10 of 566Source NIH's project files
See all 566 nih grantsPapers502
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Glycosylation-Associated Macrophage Signatures Define a Diagnostic Model for Diabetic Retinopathy via Single-Cell Analysis. | J Ophthalmol | 2026 | 42662694 | PubTator, text mining | PubMed |
| ATF4, ZIK1, and PNMA3 Transcriptomic Signatures Predict Chemoradiotherapy Response in Cervical Cancer. | Cancer Med | 2026 | 42509645 | PubTator, text mining | PubMed |
| Identification and molecular typing of disulfidptosis-related biomarkers in anaplastic thyroid carcinoma. | Cell Death Discov | 2026 | 42020364 | PubTator, text mining | PubMed |
| Systematic Druggable Genome-Wide Analysis Identifies Therapeutic Targets for Aging: A Mendelian Randomization Study. | Health Sci Rep | 2026 | 42005663 | PubTator, text mining | PubMed |
| Molecular heterogeneity of HPV-associated cancers and strategies to overcome treatment resistance. | Cancer Heterog Plast | 2026 | 41938668 | PubTator, text mining | PubMed |
| Tumor cell villages define the co-dependency of tumor and microenvironment in liver cancer. | Nat Commun | 2026 | 41723121 | PubTator, text mining | PubMed |
| Spatial transcriptomics identifies IL-32 as a lipid droplet-associated cytokine linked to tubular injury in human diabetic kidney disease. | Inflamm Res | 2026 | 41653322 | PubTator, text mining | PubMed |
| Single-cell spatial transcriptomics uncovers niches that govern response to PD-1/PD-L1 blockade in cutaneous squamous cell carcinoma. | J Immunother Cancer | 2026 | 41617396 | PubTator, text mining | PubMed |
| Development of a unified mass cytometry assay integrating activation-induced markers (AIMs) and cytokine profiling for high-throughput assessment of antigen-specific T cell responses. | Hum Vaccin Immunother | 2026 | 41614453 | PubTator, text mining | PubMed |
| GLP-1 Targeting Agents Impair Chemoimmunotherapy Effectiveness in Triple-Negative Breast Cancer. | Res Sq | 2026 | 41542041 | PubTator, text mining | PubMed |
1 to 10 of 502
See all 502 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/483
GET https://conductscience.org/api/genes/v1/483/patents?page=2